Vistagen Therapeutics (VTGN) Income from Continuing Operations (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Income from Continuing Operations of 16296000.0 for Q1 2026, up 13.77% sequentially from 18899000.0 in Q4 2025, and down 19.61% YoY from 20271795.47 in Q1 2025.
Vistagen Therapeutics (VTGN) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Income from Continuing Operations for 15 years, with the latest figure at 16296000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 19.61% year-over-year to 16296000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 69707000.0 (down 35.6% YoY) and the FY2026 annual result came in at 69707000.0, down 35.6% from the prior year.
- Income from Continuing Operations rose to 16296000.0 in Q1 2026 per VTGN's latest filing, from 18899000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 6350000.0 in Q4 2023 and troughed at 19776300.0 in Q2 2022.
- A 5-year average of 13318335.29 and a median of 13624000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations sank 168.68% in 2022, then surged 65.09% in 2023.
- Over 5 years, Income from Continuing Operations stood at 9761200.0 in 2022, then jumped by 34.95% to 6350000.0 in 2023, then sank by 121.87% to 14089000.0 in 2024, then slumped by 34.14% to 18899000.0 in 2025, then increased by 13.77% to 16296000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 16296000.0, 18899000.0, and 19417000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - | -13.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.30 Mn |
| Dec 31, 2025 | -18.90 Mn |
| Sep 30, 2025 | -19.42 Mn |
| Jun 30, 2025 | -15.10 Mn |
| Mar 31, 2025 | -13.62 Mn |
| Dec 31, 2024 | -14.09 Mn |
| Sep 30, 2024 | -12.96 Mn |
| Jun 30, 2024 | -10.73 Mn |
| Mar 31, 2024 | -9.52 Mn |
| Dec 31, 2023 | -6.35 Mn |
| Sep 30, 2023 | -6.59 Mn |
| Jun 30, 2023 | -6.90 Mn |
| Mar 31, 2023 | -12.23 Mn |
| Dec 31, 2022 | -9.76 Mn |
| Sep 30, 2022 | -17.48 Mn |
| Jun 30, 2022 | -19.78 Mn |
| Mar 31, 2022 | -16.69 Mn |
| Dec 31, 2021 | -10.53 Mn |
| Sep 30, 2021 | -12.80 Mn |
| Jun 30, 2021 | -7.75 Mn |